Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Liabilities and Shareholders Equity: 2013-2025

Historic Liabilities and Shareholders Equity for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $516.5 million.

  • Coherus Oncology's Liabilities and Shareholders Equity rose 2.28% to $516.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 30.99%. This contributed to the annual value of $448.5 million for FY2024, which is 28.76% down from last year.
  • Latest data reveals that Coherus Oncology reported Liabilities and Shareholders Equity of $516.5 million as of Q3 2025, which was up 17.53% from $439.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Liabilities and Shareholders Equity registered a high of $763.5 million during Q1 2024, and its lowest value of $371.1 million during Q1 2025.
  • For the 3-year period, Coherus Oncology's Liabilities and Shareholders Equity averaged around $527.7 million, with its median value being $505.0 million (2024).
  • Per our database at Business Quant, Coherus Oncology's Liabilities and Shareholders Equity soared by 89.74% in 2024 and then slumped by 51.40% in 2025.
  • Over the past 5 years, Coherus Oncology's Liabilities and Shareholders Equity (Quarterly) stood at $679.3 million in 2021, then fell by 29.22% to $480.8 million in 2022, then soared by 30.94% to $629.6 million in 2023, then fell by 28.76% to $448.5 million in 2024, then grew by 2.28% to $516.5 million in 2025.
  • Its last three reported values are $516.5 million in Q3 2025, $439.5 million for Q2 2025, and $371.1 million during Q1 2025.